ARTICLE | Clinical News

Sanifit's SNF472 meets in Phase II for rare vascular calcification syndrome

March 9, 2018 5:16 PM UTC

Laboratoris Sanifit S.L. (Palma de Mallorca, Spain) said IV SNF472 met the primary endpoint of improving wound healing from baseline to week 12 as measured by the Bates-Jensen Wound Assessment Tool (BWAT) in a single-arm Phase II trial to treat calciphylaxis. SNF472 also met the secondary endpoint of reducing pain. The company declined to disclose details.

The open-label, international trial enrolled about 15 hemodialysis patients with calciphylaxis, a rare and severe vascular calcification and thrombosis syndrome...

BCIQ Company Profiles

Sanifit Therapeutics S.A.